[1]王 伟,马丽华,鞠 上.投杯汤治疗支气管哮喘疗效及对患者气道重塑和气道炎症的影响[J].陕西中医,2023,(8):1047-1051.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.011]
　WANG Wei,MA Lihua,JU Shang.Effect of Toubei decoction on bronchial asthma and its influence on airway remodeling and inflammation[J].,2023,(8):1047-1051.[doi:DOI:10.3969/j.issn.1000-7369.2023.08.011]
点击复制

投杯汤治疗支气管哮喘疗效及对患者气道重塑和气道炎症的影响
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年8期
页码:
1047-1051
栏目:
临床研究
出版日期:
2023-08-05

文章信息/Info

Title:
Effect of Toubei decoction on bronchial asthma and its influence on airway remodeling and inflammation
作者:
王 伟1; 马丽华1; 鞠 上2
(1.中国中医科学院广安门医院南区,北京 102600; 2.北京中医药大学东直门医院,北京 100061)
Author(s):
WANG Wei; MA Lihua; JU Shang
(Southern Campus of Guang'anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 102600,China)
关键词:
支气管哮喘;  投杯汤;  肺脾两虚;  肺功能;  气道重塑;  炎症
Keywords:
Bronchial asthma;  Toubei decoction;  Deficiency of lung and spleen;  Pulmonary function;  Airway remodeling;  Inflammation
分类号:
R 562.2
DOI:
DOI:10.3969/j.issn.1000-7369.2023.08.011
文献标志码:
A
摘要:
目的:探究投杯汤治疗支气管哮喘疗效并分析其对患者气道重塑、气道炎症的影响。方法:选取180例肺脾两虚型支气管哮喘患者,随机分为研究组和对照组,各90例,对照组予沙美特罗替卡松粉吸入剂治疗,研究组在对照组基础上给予投杯汤治疗。对比两组疗效、肺功能、不良反应、哮喘控制水平、中医症候积分、气道重塑、气道炎症指标变化。结果:研究组总有效率95.56%显著高于对照组的83.33%(P<0.05)。两组治疗后肺功能指标用力呼气肺活量(FVC)、第一秒用力呼气容积(FEV1)和最大呼气峰流速(PEF)、最大呼气中期流速(MMF)和哮喘控制测试表(ACT)评分显著高于治疗前,且研究组显著高于对照组(均P<0.05)。两组治疗后中医症候积分、白介素-6(IL-6)、白介素-8(IL-8)、免疫球蛋白E(IgE)、外周血嗜酸性粒细胞(EOS)计数显著低于治疗前,研究组低于对照组(均P<0.05)。两组治疗后人基质金属蛋白酶组织抑制因子1(TIMP-1)、血管内皮生长因子(VEGF)、管壁面积(WA)较治疗前降低,管腔面积(LA)较治疗前升高(均P<0.05); 治疗后研究组TIMP-1、VEGF、WA低于对照组,LA高于对照组(均P<0.05)。随访期间,研究组治疗后6、12个月复发率和ACT评分显著优于对照组(均P<0.05)。结论:投杯汤联合沙美特罗替卡松粉吸入剂治疗支气管哮喘可显著改善患者肺功能和通气情况,并降低气道炎症。
Abstract:
Objective:To explore the efficacy of Toubei decoction in the treatment of bronchial asthma,and analyze its impact on airway remodeling and inflammation in patients.Methods:180 cases of bronchial asthma with deficiency of lung and spleen were randomly divided into research group and control group,with 90 cases each group.The control group was treated with meteroticasone powder inhalation,the research group was treated with Toubei decoction on this basis.Compare the curative effect,pulmonary function,adverse reactions,asthma control level,TCM syndrome score,airway remodeling,and changes in airway inflammation between the two groups.Results:The total effective rate was 95.56% in the research group,which was significantly higher than 83.33% in the control group(P<0.05).The lung function indicators FVC,FEV1,PEF,MMF and ACT scores in the two groups were significantly higher after treatment than before treatment,the research group was significantly higher than in the control group(all P<0.05).After treatment,the TCM syndrome scores,IL-6,IL-8,IgE and EOS in the two groups were significantly lower than those before treatment,while those in the research group were lower than in the control group(all P<0.05).After treatment,TIMP-1,VEGF and WA in both groups decreased compared to before treatment,while LA increased compared to before treatment(all P<0.05).After treatment,TIMP-1,VEGF and WA in the research group were lower than those in the control group,while LA in the research group was higher than that in the control group(all P<0.05).During the follow-up period,the recurrence rate and ACT score of the research group were significantly better than those of the control group at 6 and 12 months after treatment(all P<0.05).Conclusion:In the treatment of bronchial asthma,Toubei decoction combined with meteroticasone powder inhalant can significantly improve lung function and ventilation,and reduce airway inflammation.

参考文献/References:

[1] Szefler SJ,Fitzgerald DA,Adachi Y,et al.A worldwide charter for all children with asthma[J].Pediatr Pulmonol,2020,55(5):1282-1292.
[2] Lin SC,Shi LS,Ye YL,et al.Advanced molecular knowledge of therapeutic drugs and natural products focusing on inflammatory cytokines in asthma[J].Cells,2019,8(7):685.
[3] Rathod A,Zhang H,Arshad SH,et al.DNA methylation and asthma acquisition during adolescence and post-adolescence,an epigenome-wide longitudinal study[J].J Pers Med,2022,12(2):202.
[4] Franco LM,Gadkari M,Howe KN,et al.Immune regulation by glucocorticoids can be linked to cell type-dependent transcriptional responses[J].J Exp Med,2019,216(2):384-406.
[5] Zhou XJ,Qin Z.Efficacy and safety of salmeterol/fluticasone compared with montelukast alone(or add-on therapy to fluticasone)in the treatment of bronchial asthma in children and adolescents:A systematic review and meta-analysis[J].Chinese Medical Journal,134(24),2954-2961.
[6] Fatima N,Patel SN,Hussain T,et al.Angiotensin Ⅱ type 2 receptor:A target for protection against hypertension, metabolic dysfunction, and organ remodeling[J].Hypertension,2021,77(6):1845-1856.
[7] 李成辉,任宝琦,黄 镛.支气管哮喘中医证候的现代文献研究[J].中国中医急症,2021,30(5):790-792.
[8] 沈世平,薛 征.虫类中药治疗儿童支气管哮喘研究进展[J].陕西中医,2022,43(10):1484-1486.
[9] 华 雯,黄华琼,沈华浩.《支气管哮喘防治指南(2016年版)》解读[J].浙江大学学报:医学版,2016,45(5):446-451.
[10] 国家食品药品监督管理总局.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:46-48.
[11] 中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2020年版)[J].中华结核和呼吸杂志,2020,43(12):1023-1048.
[12] Weinstein SM,Pugach O,Rosales G,et al.Psychosocial moderators and outcomes of a randomized effectiveness trial for child asthma[J].J Pediatr Psychol,2021,46(6):673-687.
[13] Hamelmann E,Mutius E,Bush A,et al.Addressing the risk domain in the long-term management of pediatric asthma[J].Pediatr Allergy Immunol,2020,31(3):233-242.
[14] Breiteneder H,Peng YQ,Agache I,et al.Biomarkers for diagnosis and prediction of therapy responses in allergic diseases and asthma[J].Allergy,2020,75(12):3039-3068.
[15] 章雄英,张 艳.名老中医徐志瑛教授清润健脾益肾法治疗支气管哮喘经验[J].中华中医药学刊,2021,39(11):214-217.
[16] 王 珊,程亚伟,陈 磊,等.温肺健脾化痰汤配合热敏灸对支气管哮喘慢性持续期痰哮证患者中医证候积分及Th17/Treg平衡的影响[J].陕西中医,2022,43(1):58-61.
[17] 吴文玉,张玺金,王 凯,等.肺脾相关理论在肺系疾病中的运用[J].陕西中医,2023,44(1):88-92.
[18] 加梦还,张彩荣,冯龙飞,等.基于网络药理学探究麻黄附子细辛汤治疗哮喘的分子作用机制[J].中国医药导报,2021,18(28):35-39,封4.
[19] 唐 农,李宗友,亢 力,等.基于文献的中医治疗哮喘辨证用药规律分析[J].国际中医中药杂志,2019,41(12):1370-1374.
[20] 刘 健,孙增涛,封继宏,等.中药干预支气管哮喘气道重塑作用机制研究进展[J].中国中医急症,2018,27(8):1489-1491.
[21] 许 照,王 展,周开放,等.麻黄-杏仁对药对组胺大鼠气道上皮细胞损伤模型EGFR与PI3K表达的影响[J].中药材,2018,41(9):6.
[22] 王艳宏,包 蕾,刘振强,等.麻黄附子细辛汤药理作用研究进展[J].时珍国医国药,2010,21(1):216-217.
[23] 钟云青,王秀峰,杨树栋,等.款冬花散对支气管扩张症大鼠气道黏液高分泌影响的实验研究[J].辽宁中医药大学学报,2022,24(5):19-22,封3.
[24] Yamaya M,Nomura K,Arakawa K,et al.Clarithromycin decreases rhinovirus replication and cytokine production in nasal epithelial cells from subjects with bronchial asthma:Effects on IL-6,IL-8 and IL-33[J].Arch Pharm Res,2020,43(5):526-539.
[25] Ge Q,Moir LM,Black JL,et al.TGFβ1 induces IL-6 and inhibits IL-8 release in human bronchial epithelial cells:The role of Smad2/3[J].J Cell Physiol,2010,225(3):846-854.
[26] 王 鹏.中药治疗慢性肺源性心脏病(急性期)用药规律及网络药理学分析[D].广州:广州中医药大学,2021.

相似文献/References:

[1]吕明辉,贾艳平,元国红.清热涤痰定喘汤联合穴位贴敷治疗儿童支气管哮喘安全性及疗效分析[J].陕西中医,2019,(1):25.
　LV Minghui,JIA Yanping,YUAN Guohong..Safety and efficacy of Qingre Ditan Dingchuan decoction combined with acupoint sticking in the treatment of bronchial asthma in children[J].,2019,(8):25.
[2]李红芬,毕玲莉,张茂华.小青龙汤联合糖皮质激素对支气管哮喘患儿气道重塑 及相关炎症因子的影响[J].陕西中医,2019,(5):631.
　LI Hongfen,BI Lingli,ZHANG Maohua..Effects of Xiaoqinglong decoction combined with glucocorticoid on airway remodeling and related inflammatory factors in children with bronchial asthma[J].,2019,(8):631.
[3]唐徐韵,陈盼碧△.穴位埋线治疗支气管哮喘的实验研究探讨*[J].陕西中医,2019,(12):1789.
[4]冷 静,王艳梅,李 慧△.理肺化瘀方治疗支气管哮喘疗效及对患者血清内IgG、IgA、IgM的变化研究*[J].陕西中医,2020,(5):618.[doi:DOI:10.3969/j.issn.10007369.2020.05.018]
　LENG Jing,WANG YanMei,LI Hui..Lifei Huayu decoction in the treatment of bronchial asthma and the change of serum IgG,IgA,IgM in patients[J].,2020,(8):618.[doi:DOI:10.3969/j.issn.10007369.2020.05.018]
[5]王兰香,李卫红,周 瑾,等.消积豁痰汤加减联合糖皮质激素治疗老年支气管哮喘临床研究[J].陕西中医,2021,(6):724.[doi:DOI:10.3969/j.issn.1000-7369.2020.06.011]
[6]何 蕊,程玉峰,李艳彬.射干麻黄汤加减对支气管哮喘疗效及患者炎症反应的影响[J].陕西中医,2021,(9):1211.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.015]
　HE Rui,CHENG Yufeng,LI Yanbin.Effect of modified Shegan Mahuang decoction on bronchial asthma and inflammation[J].,2021,(8):1211.[doi:DOI:10.3969/j.issn.1000-7369.2020.09.015]
[7]高 辉,刘 恭,韩仙菊.黄芩素上调miR-625-5p表达干预支气管哮喘小鼠的机制研究[J].陕西中医,2022,(7):838.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.005]
　GAO Hui,LIU Gong,HAN Xianju.The mechanism of baicalein up-regulating miR-625-5p expression in bronchial asthma mice[J].,2022,(8):838.[doi:DOI:10.3969/j.issn.1000-7369.2022.07.005]
[8]孟玲玉,黄 燕,包海鹏,等.加味过敏煎对支气管哮喘大鼠嗜酸性粒细胞凋亡及Fas、Bcl-2调节作用的研究[J].陕西中医,2023,(5):562.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.004]
　MENG Lingyu,HUANG Yan,BAO Haipeng,et al.Research of Jiawei Guomin decoction on eosinophil apoptosis and the regulation mechanism of Fas,Bcl-2 in bronchial asthma rats[J].,2023,(8):562.[doi:DOI:10.3969/j.issn.1000-7369.2023.05.004]
[9]季雅楠,田春燕,郭丹丹,等.基于PI3K/Akt信号通路探讨中医药治疗支气管哮喘研究进展[J].陕西中医,2023,(12):1827.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.036]
　JI Yanan,TIAN Chunyan,GUO Dandan,et al.Progress in the treatment of bronchial asthma with traditional Chinese medicine based on PI3K/Akt signaling pathway[J].,2023,(8):1827.[doi:DOI:10.3969/j.issn.1000-7369.2023.12.036]
[10]冉秦杰,黄娇娇,孟 泳.定喘汤通过miR-130a-3p调控TGF-β1通路减轻支气管哮喘大鼠气道重塑机制研究[J].陕西中医,2025,46(4):456.[doi:DOI:10.3969/j.issn.1000-7369.2025.04.005]

备注/Memo

备注/Memo:
基金项目:国家重点研发计划项目(2019YFC1709302)
更新日期/Last Update: 2023-08-10